Cancer, as a global health issue, has been attracting increasing attention from scientists, medical professionals, as well as the general population. During the past several decades, many therapeutic approaches, including surgery, chemotherapy, radiotherapy and immunotherapy, have come into play for cancer treatment. Nonetheless, many of these treatments are not personalized according to the specific situation or genetic context of a particular patient. Nowadays, precision medicine opens a new era of cancer research with the hope to provide personalized treatment for different patients.
In precision medicine, immuno-oncology therapies have revolutionized the standard of care for many types of cancer. China is quickly becoming a world leader in biopharma, with rapid build-out of gene and cell therapy production capacity and a robust pipeline of drugs in development. The emergence of these immunotherapies, along with policies made by the Chinese government to strengthen medical innovations and drug research and development (R&D), means that the immuno-oncology drug pipeline for oncology treatment will be further strengthened in China over the next 5 years. China is leading the way in data collection and analysis tools to understand human genetics and biology. Also, China leads is through the development of computational power and artificial intelligence programs to discover new drugs and treatments and deliver them to the right patients.
Under above backgrounds, Organizing Committee of 4th Annual Precision Medicine and Immuno-Oncology China Summit (PMIO 2021) is delighted to invite you to Shanghai, China on August 20-21, 2021. PMIO 2021 takes an opportunity to honor top researchers for delivering innovative solutions and technologies. The theme of the conference "Latest Innovations in Precision Medicine and Immuno-Oncology in China” is designed in order to improve the understanding, investigation, prevention and treatment of many diseases.
PMIO 2021 aims to explore the outlook and development of Personalized medicine, Biomarkers, Pharmacogenomics, Precision Immunotherapy and Gene Editing in China, which can inform future targets for industry, policy makers, and other stakeholders.